Homology Medicines (LTS:0T6G) Momentum Rank : 0 (As of Jun. 01, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Homology Medicines Momentum Rank?

Homology Medicines has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Homology Medicines Momentum Rank Related Terms

Thank you for viewing the detailed overview of Homology Medicines's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Homology Medicines (LTS:0T6G) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (LTS:0T6G) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

FIXX:USA 35H:Germany

Address

One Patriots Park, Bedford, MA, USA, 01730

Website

https://www.homologymedicines.com

Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Homology Medicines (LTS:0T6G) Headlines

No Headlines